Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes (Tables)

v3.26.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2025
Income Taxes  
Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes

​

​

​

​

​

​

​

​

​

​

Year Ended December 31,

​

​

2025

​

2024

Domestic

​

$

32,032

​

$

(19,411)

Foreign

​

​

(217)

​

​

(68)

Income (loss) before income taxes

​

$

31,815

​

$

(19,479)

 

Schedule of Provision for Income Taxes (All Current)

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

  ​ ​ ​

2025

  ​ ​ ​

2024

Current:

​

​

​

​

​

​

Federal

​

$

—

​

$

—

State

​

​

—

​

​

—

Foreign

​

​

—

​

​

—

Total current tax expense (benefit)

​

$

—

​

$

—

​

​

​

​

​

​

​

Deferred:

​

​

​

​

​

​

Federal

​

$

—

​

$

(5,483)

State

​

 

—

​

 

(175)

Foreign

​

​

103

​

​

—

Total deferred tax expense (benefit)

​

$

103

​

$

(5,658)

 

Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 2025

​

​

Amount

​

Percent

U.S. federal statutory tax rate

​

$

6,681

​

21

%

State and local income taxes, net of federal income tax effect

​

​

—

​

—

%

Foreign tax effects

​

​

103

​

—

%

Effect of cross-border tax laws

​

​

—

​

—

%

Effect of changes in tax laws or rates enacted in the current period:

​

​

​

​

​

​

Tax credits

​

​

—

​

—

%

Changes in Valuation Allowances

​

​

(2,538)

​

(8)

%

Nontaxable or nondeductible items:

​

​

​

​

​

​

Stock based compensation

​

​

(584)

​

(2)

%

Nondeductible executive compensation

​

​

735

​

2

%

Bargain purchase gain

​

​

(4,457)

​

(14)

%

Other permanent differences

​

​

163

​

1

%

Changes in unrecognized tax benefits

​

​

—

​

—

%

Effective tax rate

​

$

103

​

—

%

 

​

​

​

​

​

​

​

Year Ended December 31, 

 

​

  ​ ​ ​

2024

 

Federal tax at statutory rate

 

21

%

Stock compensation and other permanent differences

 

(2)

%

Nondeductible executive compensation

 

(2)

%

Bargain purchase gain

​

20

%

Tax benefit related to Pulmokine acquisition

​

29

%

Valuation allowance

 

(37)

%

Total

 

29

%

 

Schedule of Total Cash Paid for Income Taxes, Net of Refunds

​

​

​

​

​

Federal

​

$

277

State

​

​

—

Foreign

​

​

—

Total cash paid for income taxes, net of refunds

​

$

277

 

Components of Net Deferred Tax Assets

​

​

​

​

​

​

​

​

​

​

December 31, 

​

  ​ ​ ​

2025

  ​ ​ ​

2024

Capitalized research and development expenses

​

$

80,267

​

$

22,663

Net operating loss carryforwards

​

 

42,946

​

 

36,675

Research and development and other tax credit carryforwards

​

 

13,176

​

 

13,176

Stock compensation

​

 

4,930

​

 

5,577

Unearned revenue

​

 

960

​

 

1,250

Royalty receivable

​

​

10,931

​

​

10,717

Lease liabilities

​

​

4,850

​

​

201

Intangible Asset

​

​

6,603

​

​

—

Other

​

 

658

​

 

585

Subtotal

​

 

165,321

​

 

90,844

Less: valuation allowance

​

​

(159,927)

​

​

(85,160)

Total net deferred tax assets

​

​

5,394

​

​

5,684

​

​

​

​

​

​

​

Right-of-use assets

​

​

(55)

​

​

(69)

Intangible liability

​

​

(5,339)

​

​

(5,615)

Total deferred tax liabilities

​

 

(5,394)

​

​

(5,684)

Net deferred tax liabilities

​

$

—

​

$

—

 

Schedule of Unrecognized Tax Benefits

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

  ​ ​ ​

2025

  ​ ​ ​

2024

Balance as of January 1

​

$

5,938

​

$

5,938

Increase related to current year tax position

​

 

—

​

 

—

(Decrease) Increase related to prior year tax position

​

 

—

​

 

—

Balance as of December 31

​

$

5,938

​

$

5,938